RxDoctor Payments Data

Janice Huang, MD

Cardiovascular Disease · Rochester, NYNPI 1528114154

Payments from drug & device makers

$19,576in general payments, 2019–2025

Across 81 payments — averaging $241.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$16K
  • Abbott$3K
  • Abiomed$248
  • Cvrx, Inc.$228
  • Pfizer$188
  • Novartis$93
  • plus $137 from 4 others

What the payments were for

  • Travel & lodging$1,19231%
  • Food & beverage$2,61269%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,576 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$38,074
Medicare patients
125
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndaqelTafamidis Meglumine22$491,467
FarxigaDapagliflozin Propanediol22$23,749
EliquisApixaban24$20,344
JardianceEmpagliflozin23$17,845
Potassium Chloride67$3,594
Torsemide76$1,583
Carvedilol61$838
Atorvastatin Calcium48$619
Metoprolol Succinate42$522
Eplerenone14$363
Spironolactone47$336
Amlodipine Besylate27$259
Ezetimibe12$258
Metolazone11$257
Losartan Potassium30$255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndaqel, Eliquis$188$511,81046 claims
Boehringer IngelheimJardiance$35$17,84523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →